ALK-ABELLÓ A/S |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 147.6 DKK | -3.43% |
|
-0.07% | +51.09% |
| 05-30 | Alk's European Registration Application for Itulazax for Pneumiatric Indication Accepted for Review | CI |
| 05-03 | Transcript : ALK-Abelló A/S, Q1 2024 Earnings Call, May 03, 2024 |
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ALK-ABELLÓ A/S | Other Pharmaceuticals | +0.20% | -0.07% | +51.09% | +86.46% | +99.74% | 4.94B |  | | |
- Stock Market
- Equities
- ALK B Stock
- Charts ALK-Abelló A/S
- Relative Strength Chart